Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 8 of the 85 sources its claims cite were checked for support.

Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US

Open access
Pearson, Steven D, Whaley, Christopher M, Emond, Sarah K · 2025 · Journal of Comparative Effectiveness Research

Abstract

Glucagon-like peptide 1 receptor agonists and glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonists offer weight reduction and associated health benefits that, if sustained over time, have the potential to markedly improve population health. However, over 40% of US adults have obesity, translating into more than 100 million potential new users of obesity medications. Standing in the way of the major opportunity to improve health for these individuals is the massive and likely ongoing cost of treating such a large segment of the population, even though use of the treatments is estimated to be cost-effective over a lifetime. This paper analyzes the range of emerging market approaches and policy reforms that have the potential to help the broader US health system achieve affordable and equitable access to these medications, and the relative advantages, barriers and possible unintended consequences of each approach. We seek to present policymakers and industry leaders with insights and lessons learned from experts while offering a menu of options for the future that will help all stakeholders play an active part in an innovative future of pricing, coverage and payment for new obesity medications.

Overview

CoChat Summary

## TL;DR

This white paper reviews market strategies and federal policy options to improve affordable and equitable access to GLP-1 obesity medications in the US. It argues that these drugs are clinically promising but that their very large potential uptake and high ongoing costs create major coverage, pricing, and equity challenges.

## Key findings

  • GLP-1 receptor agonists and GLP-1/GIP receptor agonists can produce substantial weight loss and may improve outcomes such as cardiovascular events and obstructive sleep apnea, but the paper emphasizes that long-term durability and safety for obesity treatment remain uncertain.
  • The scale of the target population is very large: over 40% of US adults have obesity, translating into more than 100 million potential new users of obesity medications.
  • Current commercial net prices for GLP-1s used for obesity are reported at approximately $8,000–$9,000 annually in the US market, while direct-to-consumer cash prices are about $499 per month ($5,988 annually).
  • The paper notes that some analysts estimate spending on this drug class could exceed $100 billion annually within 5 years; it also cites examples of major cost growth, including Blue Cross Blue Shield of Massachusetts reporting more than $300 million in GLP-1 costs in 2024 and a $400 million operating loss.

## Methods

  • The paper used a targeted literature review of peer-reviewed and gray literature on obesity medications in the US, plus clinical guidelines, professional society publications, purchaser coalition white papers, and patient advocacy materials.
  • The authors conducted 14 interviews of 45 minutes each with policy experts, including pharmacy benefit managers, manufacturers, patient advocacy groups, purchasers, benefit consultants, and state/Medicaid experts; they also note a 2-day meeting in December 2024 with senior policy leaders from 26 payer and life science companies and other stakeholders.
  • The analysis is a policy review: it synthesizes expert input and literature to compare market strategies and federal policy interventions, weighing advantages, barriers, and unintended consequences rather than testing an empirical intervention.

## Limitations

  • The paper states that no single market action or policy reform is a “silver bullet,” and that the evidence base is incomplete for several proposed approaches, including step therapy, time-limited treatment, screening tools, and carve-out programs.
  • It explicitly notes that there are no publicly available data for some outcomes of interest, including outcomes after switching from one GLP-1 to another, and that there are no rigorous trials for some carve-out program components.
  • Evident from the text: this is not an outcome study but a narrative/policy analysis based on literature and expert interviews, so its conclusions are dependent on rapidly changing coverage, pricing, and regulatory conditions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.57264/cer-2025-0083

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

7 Valid · 17 Not valid · 68 Not checked · 92 Own results and interpretations

62 more claims

Create a free account to see all 184 claims and to verify the 25 references still open.

See all claims — free account
  • It may state two separate claims as one. 60
  • Probably not a substantial claim. 79

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 22 references

Research works printed but not linked: 18

  1. Institute for Clinical and Economic Review. Medications for obesity management: effectiveness and value. (2022). Available at: https://icer.org/wp-content/uploads/2022/03/ICER_Obesity_Final_Evidence_Report_and_Meeting_Summary_122223.pdf
  2. Marshall LZ, Urick BY, Friedlander N Two-year persistent glucagon-like peptide-1 agonist obesity without diabetes treatment: clinical outcomes among commercially insured. In: AMCP Annual Meeting, Prime Therapeutics, TX, USA (2025). Available at: https://www.primetherapeutics.com/documents/d/primetherapeutics/4085-d_amcp_spring25_glp1apersistentclinicaloutcomes_r4-1
  3. Sharma A. Eli Lilly resolves shortage for tirzepatide, potentially ending compounders' run. Endpoints News (2024). Available at: https://endpts.com/eli-lilly-resolves-shortage-for-tirzepatide-ending-compounders-run/
  4. Sutter S. US FDA employs familiar strategy in ending Novo's Wegovy, Ozempic shortage. Citeline (2025). Available at: https://insights.citeline.com/pink-sheet/compliance/distribution-supply-chain/us-fda-employs-familiar-strategy-in-ending-novos-wegovy-ozempic-shortage-XWRMJ2WTPNCXTEHHJEXJAJE2QY/
  5. Carbajal E. 1% of ACA health plans cover GLP-1s for weight loss. KFF (2024). Available at: https://www.beckerspayer.com/payer/1-of-aca-health-plans-cover-glp-1s-for-weight-loss-kff/
  6. Wilson R. Employers are worried about GLP-1s – most cover them anyway. Becker's Payer Issues (2024). Available at: https://www.beckerspayer.com/payer/employers-are-worried-about-glp-1s-most-cover-them-anyway/
  7. Goforth A. North Carolina ends coverage of new weight loss drugs for 750,000 state employees. BenefitsPRO (2024). Available at: https://www.benefitspro.com/2024/05/17/north-carolina-ends-coverage-of-glp-1-weight-loss-drugs-for-750000-state-employees/?slreturn=20241106182539
  8. Sellers M. Blue Cross Blue Shield of Massachusetts faces record-breaking $400 million operating loss in 2024. Insurance Business Magazine (2025). Available at: https://www.insurancebusinessmag.com/us/news/life-insurance/blue-cross-blue-shield-of-massachusetts-faces-recordbreaking-400-million-operating-loss-in-2024-526958.aspx
  9. McGough M, Lo J, Tevis D, Rae M, Cox C. How many adults with private health insurance could use GLP-1 drugs. Peterson-KFF (2024). Available at: https://www.healthsystemtracker.org/brief/how-many-adults-with-private-health-insurance-could-use-glp-1-drugs/
  10. FormHealth. Dedicated clinical care to make lasting change. FormHealth (2025). Available at: https://www.formhealth.co/how-it-works
  11. Phenomix Sciences. Phenomix Sciences and InformedDNA partner to advance genetics-driven obesity care. Phenomix Sciences (2024). Available at: https://www.phenomixsciences.com/about/press/phenomix-sciences-and-informeddna-partner-advance-genetics-driven-obesity-care#:∼:text=The%20MyPhenome%20test%20is%20a,treatments%2C%20including%20GLP%2D1s
  12. Palmer K. During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less. STAT (2025). Available at: https://www.statnews.com/2025/01/16/jp-morgan-conference-virtual-care-companies-glp-plans/
  13. Calibrate. Calibrate delivers longitudinal real-world outcomes with sustained weight loss and metabolic health improvements. Calibrate (2025). calibrate.cdn.priscmic.io. Available at: https://calibrate.cdn.prismic.io/calibrate/Z4VCK5bqstJ99ZFD_2025ResultsReportWhitePaper-1-.pdf
  14. Institute for Clinical and Economic Review. Cornerstones of ‘fair’ drug coverage. (2020). Available at: https://icer.org/assessment/cornerstones-of-fair-drug-coverage-2020/
  15. Baghdadi R. Medicaid best price. HealthAffairs (2017). Available at: https://www.healthaffairs.org/content/briefs/medicaid-best-pricehttps://www.healthaffairs.org/content/briefs/medicaid-best-price
  16. Fitch ME. CT state employees losing weight on medication, but costs top $35 million. Inside Investigator (2024). Available at: https://insideinvestigator.org/ct-state-employees-losing-weight-on-medication-but-costs-top-35-million/
  17. Pifer R. Why Cigna is capping cost increases for pricey GLP-1 weight loss drugs. MedTechDive (2024). Available at: https://www.medtechdive.com/news/cigna-glp-1-cost-cap-employers-pbm/709770/
  18. Nania R. Medicare unveils first negotiated prices for 10 of the costliest medications. AARP (2024). Available at: https://www.aarp.org/politics-society/advocacy/info-2024/medicare-drug-price-list.html

Cited by

See all 55

Metadata

Authors
Pearson, S. D., Whaley, C. M., & Emond, S. K.
Affiliations
  • Institute for Clinical and Economic Review (US)
  • Brown University (US)
Corresponding author
Emond, Sarah K
Venue
Journal of Comparative Effectiveness Research
Published
2025-09
Volume
14
Issue
9
Pages
e250083-e250083
ISSN
  • 2042-6305 (ISSN-L)
  • 2042-6313
OpenAlex
W4412191076
Cited by
55
References
22
Citations by year
2026: 52 · 2025: 3
FWCI
37.17
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Journal of Comparative Effectiveness Research (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
Keywords
GLP-1 receptor agonists, anti-obesity drugs, drug pricing, access to medicines, health policy, pharmaceutical market, insurance coverage, payment models, cost-effectiveness, health equity
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Health Policy, Health Services Accessibility, Humans, Obesity, United States, Drug Costs, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. https://app.cochat.ai/papers/10.57264/cer-2025-0083
The paper
Pearson, S. D., Whaley, C. M., & Emond, S. K. (2025). Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0083

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.